CFO
ONC

Callan Family Office’s BeOne Medicines Ltd ONC Stock Holding History

Callan Family Office’s Portfolio ONC Stock Details ONC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$720K Sell
2,423
-251
-9% -$81.2K 0.02% 651
2025
Q4 		$812K Buy
2,674
+1,743
+187% +$571K 0.02% 610
2025
Q3 		$317K Sell
931
-94
-9% -$28.5K 0.01% 691
2025
Q2 		$248K Buy
+1,025
New +$251K 0.01% 831

Other funds holding ONC

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Callan Family Office's ONC Position: Q1 2026 in Review

Callan Family Office reduced its BeOne Medicines Ltd (ONC) stake by 9.4% in Q1 2026, selling an estimated $81.2K and leaving 2,423 shares worth $720K. The position accounts for 0.02% of the portfolio, ranked #651.

Callan Family Office first reported a position in ONC in Q2 2025 and has held it in 4 quarters since. The position peaked at $812K in Q4 2025. 281 funds tracked by Wall St. Rank hold ONC as of Q1 2026.

  • Callan Family Office held 2,423 shares of BeOne Medicines Ltd worth $720K as of Q1 2026.
  • Callan Family Office sold 251 BeOne Medicines Ltd shares in Q1 2026, an estimated $81.2K.
  • BeOne Medicines Ltd made up 0.02% of Callan Family Office's portfolio in Q1 2026, its #651 holding.
  • Callan Family Office first reported a position in BeOne Medicines Ltd in Q2 2025 and has held it in 4 quarters since.
  • Callan Family Office's BeOne Medicines Ltd position peaked at $812K in Q4 2025.
  • 281 funds tracked by Wall St. Rank held BeOne Medicines Ltd as of Q1 2026.

Based on Callan Family Office's 13F filing for Q1 2026, filed 13 May 2026.